Abstract
The accuracy of positron emission tomography (PET)/CT with [{sup 11}C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [{sup 11}C]choline maximum standardized uptake values (SUV{sub max}) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. In this prospective study, PET/CT with [{sup 11}C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B). In group A, based on a sextant analysis with a [{sup 11}C]choline SUV{sub max} cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUV{sub max} and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P < 0.05) negative correlation was detected between SUV{sub max} and anti-androgenic therapy both in univariate (r {sup 2} = 0.24) and multivariate (r {sup 2} = 0.48) analyses. Prostate [{sup 11}C]choline
More>>
Giovacchini, Giampiero;
Coradeschi, Elisa;
[1]
Picchio, Maria;
Bettinardi, Valentino;
[2]
Scattoni, Vincenzo;
[3]
Cozzarini, Cesare;
[4]
Freschi, Massimo;
[5]
Fazio, Ferruccio;
[1]
Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy);
Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy);
National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy)];
Messa, Cristina;
[1]
National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy);
University of Milano-Bicocca, Department Nuclear Medicine, San Gerardo Hospital, Monza (Italy)]
- University of Milano-Bicocca, Center for Molecular Bioimaging, Milan (Italy)
- Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy)
- Scientific Institute San Raffaele, Department of Urology, Milan (Italy)
- Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy)
- Scientific Institute San Raffaele, Department of Pathology, Milan (Italy)
Citation Formats
Giovacchini, Giampiero, Coradeschi, Elisa, Picchio, Maria, Bettinardi, Valentino, Scattoni, Vincenzo, Cozzarini, Cesare, Freschi, Massimo, Fazio, Ferruccio, Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy), Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy), National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy)], Messa, Cristina, National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy), and University of Milano-Bicocca, Department Nuclear Medicine, San Gerardo Hospital, Monza (Italy)].
[{sup 11}C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.
Germany: N. p.,
2008.
Web.
doi:10.1007/S00259-008-0716-2.
Giovacchini, Giampiero, Coradeschi, Elisa, Picchio, Maria, Bettinardi, Valentino, Scattoni, Vincenzo, Cozzarini, Cesare, Freschi, Massimo, Fazio, Ferruccio, Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy), Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy), National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy)], Messa, Cristina, National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy), & University of Milano-Bicocca, Department Nuclear Medicine, San Gerardo Hospital, Monza (Italy)].
[{sup 11}C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.
Germany.
https://doi.org/10.1007/S00259-008-0716-2
Giovacchini, Giampiero, Coradeschi, Elisa, Picchio, Maria, Bettinardi, Valentino, Scattoni, Vincenzo, Cozzarini, Cesare, Freschi, Massimo, Fazio, Ferruccio, Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy), Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy), National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy)], Messa, Cristina, National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy), and University of Milano-Bicocca, Department Nuclear Medicine, San Gerardo Hospital, Monza (Italy)].
2008.
"[{sup 11}C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy."
Germany.
https://doi.org/10.1007/S00259-008-0716-2.
@misc{etde_21044456,
title = {[{sup 11}C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy}
author = {Giovacchini, Giampiero, Coradeschi, Elisa, Picchio, Maria, Bettinardi, Valentino, Scattoni, Vincenzo, Cozzarini, Cesare, Freschi, Massimo, Fazio, Ferruccio, Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy), Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy), National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy)], Messa, Cristina, National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy), and University of Milano-Bicocca, Department Nuclear Medicine, San Gerardo Hospital, Monza (Italy)]}
abstractNote = {The accuracy of positron emission tomography (PET)/CT with [{sup 11}C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [{sup 11}C]choline maximum standardized uptake values (SUV{sub max}) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. In this prospective study, PET/CT with [{sup 11}C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B). In group A, based on a sextant analysis with a [{sup 11}C]choline SUV{sub max} cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUV{sub max} and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P < 0.05) negative correlation was detected between SUV{sub max} and anti-androgenic therapy both in univariate (r {sup 2} = 0.24) and multivariate (r {sup 2} = 0.48) analyses. Prostate [{sup 11}C]choline uptake after bicalutamide therapy significantly (P < 0.05) decreased compared to baseline (6.4 {+-} 4.6 and 11.8 {+-} 5.3, respectively; group B). PET/CT with [{sup 11}C]choline is not suitable for the initial diagnosis and local staging of prostate cancer. PET/CT with [{sup 11}C]choline could be used to monitor the response to anti-androgenic therapy. (orig.)}
doi = {10.1007/S00259-008-0716-2}
journal = []
issue = {6}
volume = {35}
place = {Germany}
year = {2008}
month = {Jun}
}
title = {[{sup 11}C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy}
author = {Giovacchini, Giampiero, Coradeschi, Elisa, Picchio, Maria, Bettinardi, Valentino, Scattoni, Vincenzo, Cozzarini, Cesare, Freschi, Massimo, Fazio, Ferruccio, Scientific Institute San Raffaele, Department of Nuclear Medicine, Milan (Italy), Scientific Institute San Raffaele, Department of Radiation Oncology, Milan (Italy), National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy)], Messa, Cristina, National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy), and University of Milano-Bicocca, Department Nuclear Medicine, San Gerardo Hospital, Monza (Italy)]}
abstractNote = {The accuracy of positron emission tomography (PET)/CT with [{sup 11}C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [{sup 11}C]choline maximum standardized uptake values (SUV{sub max}) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. In this prospective study, PET/CT with [{sup 11}C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B). In group A, based on a sextant analysis with a [{sup 11}C]choline SUV{sub max} cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUV{sub max} and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P < 0.05) negative correlation was detected between SUV{sub max} and anti-androgenic therapy both in univariate (r {sup 2} = 0.24) and multivariate (r {sup 2} = 0.48) analyses. Prostate [{sup 11}C]choline uptake after bicalutamide therapy significantly (P < 0.05) decreased compared to baseline (6.4 {+-} 4.6 and 11.8 {+-} 5.3, respectively; group B). PET/CT with [{sup 11}C]choline is not suitable for the initial diagnosis and local staging of prostate cancer. PET/CT with [{sup 11}C]choline could be used to monitor the response to anti-androgenic therapy. (orig.)}
doi = {10.1007/S00259-008-0716-2}
journal = []
issue = {6}
volume = {35}
place = {Germany}
year = {2008}
month = {Jun}
}